These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 33552852)

  • 21. Efficiently restoring the tumoricidal immunity against resistant malignancies via an immune nanomodulator.
    Chen C; Li A; Sun P; Xu J; Du W; Zhang J; Liu Y; Zhang R; Zhang S; Yang Z; Tang C; Jiang X
    J Control Release; 2020 Aug; 324():574-585. PubMed ID: 32473178
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Blocking CXCR4 alleviates desmoplasia, increases T-lymphocyte infiltration, and improves immunotherapy in metastatic breast cancer.
    Chen IX; Chauhan VP; Posada J; Ng MR; Wu MW; Adstamongkonkul P; Huang P; Lindeman N; Langer R; Jain RK
    Proc Natl Acad Sci U S A; 2019 Mar; 116(10):4558-4566. PubMed ID: 30700545
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Towards Immunotherapy-Induced Normalization of the Tumor Microenvironment.
    Melo V; Bremer E; Martin JD
    Front Cell Dev Biol; 2022; 10():908389. PubMed ID: 35712656
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade.
    Bai X; Zhou Y; Yokota Y; Matsumoto Y; Zhai B; Maarouf N; Hayashi H; Carlson R; Zhang S; Sousa A; Sun B; Ghanbari H; Dong X; Wands JR
    J Exp Clin Cancer Res; 2022 Apr; 41(1):132. PubMed ID: 35392977
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ultrasound stiffness and perfusion markers correlate with tumor volume responses to immunotherapy.
    Voutouri C; Mpekris F; Panagi M; Krolak C; Michael C; Martin JD; Averkiou MA; Stylianopoulos T
    Acta Biomater; 2023 Sep; 167():121-134. PubMed ID: 37321529
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combination of radiation therapy, bempegaldesleukin, and checkpoint blockade eradicates advanced solid tumors and metastases in mice.
    Pieper AA; Rakhmilevich AL; Spiegelman DV; Patel RB; Birstler J; Jin WJ; Carlson PM; Charych DH; Hank JA; Erbe AK; Overwijk WW; Morris ZS; Sondel PM
    J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34172518
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tumor vasculature normalization by orally fed erlotinib to modulate the tumor microenvironment for enhanced cancer nanomedicine and immunotherapy.
    Chen Q; Xu L; Chen J; Yang Z; Liang C; Yang Y; Liu Z
    Biomaterials; 2017 Dec; 148():69-80. PubMed ID: 28968536
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chemo-photodynamic therapy with light-triggered disassembly of theranostic nanoplatform in combination with checkpoint blockade for immunotherapy of hepatocellular carcinoma.
    Xu J; Zheng Q; Cheng X; Hu S; Zhang C; Zhou X; Sun P; Wang W; Su Z; Zou T; Song Z; Xia Y; Yi X; Gao Y
    J Nanobiotechnology; 2021 Oct; 19(1):355. PubMed ID: 34717654
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reprogramming the Tumor Microenvironment to Improve Immunotherapy: Emerging Strategies and Combination Therapies.
    Datta M; Coussens LM; Nishikawa H; Hodi FS; Jain RK
    Am Soc Clin Oncol Educ Book; 2019 Jan; 39():165-174. PubMed ID: 31099649
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of histone lysine-specific demethylase 1 elicits breast tumor immunity and enhances antitumor efficacy of immune checkpoint blockade.
    Qin Y; Vasilatos SN; Chen L; Wu H; Cao Z; Fu Y; Huang M; Vlad AM; Lu B; Oesterreich S; Davidson NE; Huang Y
    Oncogene; 2019 Jan; 38(3):390-405. PubMed ID: 30111819
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmaceutical targeting Th2-mediated immunity enhances immunotherapy response in breast cancer.
    Chen Y; Sun J; Luo Y; Liu J; Wang X; Feng R; Huang J; Du H; Li Q; Tan J; Ren G; Wang X; Li H
    J Transl Med; 2022 Dec; 20(1):615. PubMed ID: 36564797
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enhanced Therapeutic Efficacy of Combining Losartan and Chemo-Immunotherapy for Triple Negative Breast Cancer.
    Zhao Q; He X; Qin X; Liu Y; Jiang H; Wang J; Wu S; Zhou R; Yu C; Liu S; Zhang H; Tian M
    Front Immunol; 2022; 13():938439. PubMed ID: 35812418
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recent advances in tumor microenvironment-targeted nanomedicine delivery approaches to overcome limitations of immune checkpoint blockade-based immunotherapy.
    Kim J; Hong J; Lee J; Fakhraei Lahiji S; Kim YH
    J Control Release; 2021 Apr; 332():109-126. PubMed ID: 33571549
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer.
    Miles D; Gligorov J; André F; Cameron D; Schneeweiss A; Barrios C; Xu B; Wardley A; Kaen D; Andrade L; Semiglazov V; Reinisch M; Patel S; Patre M; Morales L; Patel SL; Kaul M; Barata T; O'Shaughnessy J;
    Ann Oncol; 2021 Aug; 32(8):994-1004. PubMed ID: 34219000
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Carrier-Free Photodynamic Bioregulators Inhibiting Lactic Acid Efflux Combined with Immune Checkpoint Blockade for Triple-Negative Breast Cancer Immunotherapy.
    Chen G; Lin L; Mai Z; Tang Y; Zhang Q; Chen G; Li Z; Zhang J; Wang Y; Yang Y; Yu Z
    ACS Nano; 2024 Jul; ():. PubMed ID: 39034461
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nanoparticle-integrated dissolving microneedles for the co-delivery of R848/aPD-1 to synergistically reverse the immunosuppressive microenvironment of triple-negative breast cancer.
    Huang S; Wen T; Wang J; Wei H; Xiao Z; Li B; Shuai X
    Acta Biomater; 2024 Mar; 176():344-355. PubMed ID: 38244662
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel Dual-Mode NIR-II/MRI Nanoprobe Targeting PD-L1 Accurately Evaluates the Efficacy of Immunotherapy for Triple-Negative Breast Cancer.
    Liu WL; Zhang YQ; Luo XJ; Zhu YY; Song L; Ming ZH; Zhang LX; Li MJ; Lv RC; Zhang GJ; Chen M
    Int J Nanomedicine; 2023; 18():5141-5157. PubMed ID: 37705867
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Modeling resistance of colorectal peritoneal metastases to immune checkpoint blockade in humanized mice.
    Küçükköse E; Heesters BA; Villaudy J; Verheem A; Cercel M; van Hal S; Boj SF; Borel Rinkes IHM; Punt CJA; Roodhart JML; Laoukili J; Koopman M; Spits H; Kranenburg O
    J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36543378
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting Axl favors an antitumorigenic microenvironment that enhances immunotherapy responses by decreasing Hif-1α levels.
    Goyette MA; Elkholi IE; Apcher C; Kuasne H; Rothlin CV; Muller WJ; Richard DE; Park M; Gratton JP; Côté JF
    Proc Natl Acad Sci U S A; 2021 Jul; 118(29):. PubMed ID: 34266948
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vascular normalization in immunotherapy: A promising mechanisms combined with radiotherapy.
    Liu Z; Zhao Q; Zheng Z; Liu S; Meng L; Dong L; Jiang X
    Biomed Pharmacother; 2021 Jul; 139():111607. PubMed ID: 33965730
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.